Oregovomab - OncoQuest

Drug Profile

Oregovomab - OncoQuest

Alternative Names: Anti CA125 Mab oregovomab; Anti-CA125-monoclonal-antibody-B43-13-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-AltaRex; Mab B43.13; Monoclonal antibody B43.13; OvaRex; Ovarian-cancer-vaccine-AltaRex

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AltaRex
  • Developer National Cancer Centre (Singapore); National Cancer Institute (USA); OncoQuest; University of Nebraska Medical Center
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer; Pancreatic cancer
  • Phase I/II Peritoneal cancer

Most Recent Events

  • 07 Nov 2017 Efficacy data from a phase II trial in Ovarian cancer released by OncoQuest
  • 26 Oct 2017 OncoQuest and TESARO agree to co-develop oregovomab in combination with niraparib for Ovarian cancer
  • 26 Oct 2017 OncoQuest in collaboration with TESARO plans a phase I/II trial of oregovomab in combination with niraparib for Ovarian cancer (Combination therapy, Recurrent) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top